Astex Pharmaceuticals Announce Key Data Presentations at the American Association For Cancer Research (AACR) 2024 Annual Meeting
2024-04-03
临床1期AACR会议
CAMBRIDGE, United Kingdom, April 03, 2024 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it will make five key data presentations at AACR 2024 focusing on its Phase II-ready MDM2 antagonist, ASTX295. AACR 2024 will take place from April 5-10, 2024, at the San Diego Convention Center, San Diego, USA.
ASTX295 data presentations at AACR 2024
Title
Presentation
Date/Time/Presenter
Link to Abstract
Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile. From concept to clinic
Oral
Tuesday, April 9
3:20 - 3:35pm PT
Session Title: Novel Antitumor Agents 5
Presenter: Maria Ahn, Astex Pharmaceuticals, UK
6588
ASTX295 engages p53-mediated apoptosis and an inflammatory response in patient derived mesothelioma explants
Poster
Sunday, April 7
1:30 - 5:00pm PT
Presenter: Dean Fennell, University of Leicester, UK
666
link
Identification of biomarkers of response to MDM2 inhibition in solid tumours using computational, multi-omics approaches
Poster
Sunday, April 7
1:30 - 5:00pm PT
Presenter: Matthew Davis, Astex Pharmaceuticals, UK
667
Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53
Poster
Monday, April 8, 9:00 -12:30pm PT
Presenter: Ekaterina Dumbrava, The University of Texas MD Anderson
Cancer Center, Houston, TX
CT066
Targeting the MDM2-p53 interaction: Time-and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index
Poster
Monday, April 8
1:30 - 5:00pm PT
Presenter: Steve Wedge, Newcastle University, Newcastle upon Tyne, UK
3333
ASTX295 is an oral, potent inhibitor of the p53-MDM2 protein-protein interaction that was discovered by Astex using its proprietary structure-based drug design approach. The compound was specifically designed to overcome the on-target toxicity seen in the first generation MDM2 antagonist compounds which have shown dose-limiting haematological toxicities in the clinic. In contrast, ASTX295 is a potent MDM2 antagonist with a clean CYP/hERG pro a shorter human half-life allowing for pulsatile pathway modulation while avoiding myelosuppression. ASTX295 therefore has bone-marrow sparing characteristics which permit a differentiated safety pro be presented at AACR. Astex is interested in discussing the further development of ASTX295 with potential partners.
About Astex Pharmaceuticals
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. Astex is developing a proprietary pipeline of novel therapies and has a number of partnered products being developed under collaborations with leading pharmaceutical companies. Astex is a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan.
For more information about Astex Pharmaceuticals please visit:
For more information about Otsuka Pharmaceutical, please visit:
Contact
At the Company:
Jeremy Carmichael
SVP Corporate Development
Head of Business Development
Tel: +44(0)1223 226289
Email: jeremy.carmichael@astx.com
For Media Enquiries:
Sue Charles
Charles Consultants
Tel : +44 7968 726585
Email: sue@charles-consultants.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。